SINGAPORE, May 9, 2023
/PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC)
("CytoMed" or the "Company"), a biopharmaceutical company focused
on harnessing its licensed proprietary technologies to create novel
allogeneic cell-based immunotherapies for the treatment of human
cancers, today announced it has entered into a research
collaboration agreement with The University of
Texas MD Anderson Cancer Center ("MD Anderson") in Houston, Texas, to use gamma-delta T cells
(gdTc) for the treatment of acute myeloid leukemia (AML) and breast
cancer. AML is the most common type of acute leukemia in adults and
is likely to worsen quickly if untreated. However, there are not
many treatment options available for AML. Similarly, the incidence
rate of breast cancer globally is high, and patients may quickly
run out of treatment options, especially if they suffer from
triple-negative breast cancer. This collaboration aims to develop
new treatment modalities for unmet needs of AML and breast cancer
patients at an affordable cost.
The study will be led by Venkata Lokesh
Battula, Ph.D., associate professor of Leukemia at MD
Anderson. Under the terms of the
two-year agreement, research teams will evaluate the application of
CytoMed's allogeneic gdTc on various subtypes of AML and breast
cancer in vitro and in vivo. The study is expected to use
patient-derived AML cells and breast cancer cell lines for
investigation. The results of the study are intended to be part of
an Investigational New Drug Application with the U.S. Food and Drug
Administration for the allogeneic use of gdTc for blood and solid
cancers.
CytoMed received approval in January
2023 from Singapore's
Health Science Authority to conduct a first-in-human Phase I
clinical trial for the use of its lead allogeneic chimeric antigen
receptor T-cell (CAR-T) product candidate (CTM-N2D) against several
blood and solid tumor cancers, including colorectal, lung, liver,
ovarian, lymphoma and multiple myeloma [ANGELICA Trial,
NCT05302037]. This is a single-site, open-label, dose-escalating
trial at the National University,
Hospital, Singapore, an
established major public hospital.
"Interest in the potential of our allogeneic immunotherapy
platform to provide additional treatment options has been strong,"
said Dr Tan Wee Kiat, Chief
Operating Officer at CytoMed, "and international collaborations,
like the current collaboration with MD Anderson Cancer Center, are
a key part of our strategy to maximize our impact."
About CytoMed
Incorporated in 2018, CytoMed was spun off from the Agency for
Science, Technology and Research (A*STAR), Singapore's national research and development
agency in the public sector. CytoMed is a biopharmaceutical
company focused on harnessing its licensed proprietary technologies
to create novel cell-based immunotherapies for the treatment of
human cancers. The development of novel technologies has been
inspired by the clinical success of existing CAR-T in treating
hematological malignancies as well as the current clinical
limitations and commercial challenges in extrapolating the CAR-T
principle into treatment of solid tumors. For more information
about CytoMed, please visit www.cytomed.sg.
Forward-Looking Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's plans to develop and commercialize its
product candidates; the initiation, timing, progress and results of
the Company's current and future pre-clinical studies and clinical
trials and the Company's R&D programs; the Company's
expectations regarding the impact of the ongoing COVID-19 pandemic
on its business, the Company's industry and the economy; the
Company's estimates regarding expenses, future revenue, capital
requirements and needs for additional financing; the Company's
ability to successfully acquire or obtain licenses for additional
product candidates on reasonable terms; the Company's ability to
establish and maintain collaborations and/or obtain additional
funding and assumptions underlying or related to any of the
foregoing and other risks contained in reports filed by the Company
with the SEC. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the SEC, which are available for
review at www.sec.gov. The Company undertakes no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof.
Contacts
Investors:
CytoMed Therapeutics Limited
Email: enquiry@cytomed.sg
Investor Relations:
Crocker Coulson, CEO, AUM Media
+1 (646) 652-7185
crocker.coulson@aummedia.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytomed-therapeutics-limited-announces-collaboration-with-md-anderson-cancer-center-to-advance-allogeneic-off-the-shelf-gamma-delta-t-cells-in-oncology-301819685.html
SOURCE CytoMed Therapeutics
